Alkermes Initiates Phase 2 Study of ALKS 7290 in Depression
Dublin, Ireland — October 30, 2026 Alkermes plc announced the initiation of a Phase 2 clinical study evaluating ALKS...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
Dublin, Ireland — October 30, 2026 Alkermes plc announced the initiation of a Phase 2 clinical study evaluating ALKS...
Titusville, New Jersey, U.S., September 21, 2026 Johnson & Johnson has announced positive topline results from a pivotal Phase...
North Chicago, Illinois, September 18, 2026 AbbVie has announced new real-world data for VRAYLAR® (cariprazine) presented at Psych Congress...
LONDON and NEW YORK — September 15, 2026 Compass Pathways plc announced the launch of Change the Tune in...
WILMINGTON, Del. — September 11, 2026 NRx Pharmaceuticals, Inc. announced that its subsidiary HOPE Therapeutics has begun training and...
BOSTON — September 9, 2026 Seaport Therapeutics, Inc. reported positive topline results from a Phase 1 driving simulation trial...
NEW YORK — September 10, 2026 Definium Therapeutics, Inc. announced plans to present six posters and an invited oral...
AUSTIN, Texas — September 10, 2026 EPIK Biosciences announced continued progress in developing proprietary synergistic combination medicines targeting mental...
LONDON and NEW YORK — September 9, 2026 Compass Pathways plc announced positive topline 52-week open-label results from Part...
BOSTON — September 9, 2026 Seaport Therapeutics, Inc. announced positive topline results from a Phase 1 driving simulation trial...
